Evidence map›Paper›PMID 40897948›Full record

ArticleMolecular imaging and biology2025

PSMA-1-DOTA Potentially for Effective Targeted Radioligand Therapy of Prostate Cancer.

Xinning Wang, Olga Sergeeva, Maxim Sergeev, Lifang Zhang, Zoey Lockwood, Patrick Wojtylak, Riley Sangster, David Reichert, Marc Berridge, Wolfgang Weber and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular imaging and biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Xinning WangBiomedical Engineering, Case Western Reserve University, Cleveland, OH, USA.
Olga SergeevaRadiology, Case Western Reserve University, Cleveland, OH, USA.
Maxim SergeevChemistry, Case Western Reserve University, Cleveland, OH, USA.
Lifang ZhangBiomedical Engineering, Case Western Reserve University, Cleveland, OH, USA.
Zoey LockwoodChemistry, Case Western Reserve University, Cleveland, OH, USA.
Patrick WojtylakNuclear Medicine, Radiology, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.
Riley Sangster3D Imaging, LCC, Little Rock, AR, USA.
David Reichert3D Imaging, LCC, Little Rock, AR, USA.
Marc Berridge3D Imaging, LCC, Little Rock, AR, USA.
Wolfgang WeberKlinikum Rechts Der Isar, Nuklearmedizin, Technische Universität München (TUM), München, Germany.
Zhenghong LeeBiomedical Engineering, Case Western Reserve University, Cleveland, OH, USA. zxl11@case.edu.ORCID 0000-0002-2429-9911
James P BasilionBiomedical Engineering, Case Western Reserve University, Cleveland, OH, USA. jxb206@case.edu.

Funding

Fluorescence-guided resection of breast tumors using a topically-applied molecular probeR01CA246678 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI BASILION, JAMES PETER · 2020 to 2025
$2.8M
PSMA-targeted AuNPs for MR guided radiotherapy and radiosensitizationR01CA260847 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI AYDOGAN, BULENT, BASILION, JAMES PETER · 2021 to 2024
$2.6M
Highly selective targeted theranostics for prostate cancersR01CA255925 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI BASILION, JAMES PETER, HOLT, DAVID · 2021 to 2024
$2.5M
PET imaging of viral infectionR21AI163656 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI LEE, ZHENGHONG, SAUNTHARARAJAH, YOGEN · 2021 to 2022
$443k
DOD Peer Reviewed Cancer Research Program W81XWH2210784NCI NIH HHS R01 CA246678NCI NIH HHS R01CA246678NCI NIH HHS R01 CA255925NCI NIH HHS R01CA255925NCI NIH HHS R01 CA260847NCI NIH HHS R01CA260847NIAID NIH HHS R21 AI163656
6 · The paper itself

Abstract

purposeWhile PSMA-targeted radioligand therapy (RLT) has shown remarkable efficacy for treating end-stage prostate cancer, the α-emitting RLT often results in severe salivary gland toxicity, limiting its use. Various strategies to mitigate this side effect have been attempted with limited success. Accordingly, this study introduced a new PSMA-targeting ligand with more favorable binding characteristics than the existing ligands. PROCEDURES: The binding affinity of PSMA-1-DOTA to PSMA was compared with that of PSMA-11 and PSMA I&T. Comparison of uptake in the salivary glands, kidneys and PC3pip tumor cells in the xenograft mouse models between [

resultsThe binding affinity of PSMA-1-DOTA to PSMA was found to be approximately four times greater than other PSMA-targeted ligands. Imaging with microPET/CT revealed significantly lower kidney, uptake and little salivary and lacrimal gland uptake with [

conclusionPSMA-1-DOTA shows reduced uptake in salivary glands while effectively targeting PSMA-expressing tumors, thus potentially avoiding the side effects of xerostomia, and possibly moving PSMA-targeted RLT to a more frontline therapy for prostate cancer rather than the current use as a last resort.

Indexed as

Heterocyclic Compounds, 1-RingProstatic NeoplasmsRadiopharmaceuticalsAnimalsCell Line, TumorGallium RadioisotopesGlutamate Carboxypeptidase IIHumansLigandsMaleMiceMice, NudePositron Emission Tomography Computed TomographyTissue DistributionXenograft Model Antitumor Assays1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acidGallium RadioisotopesGlutamate Carboxypeptidase IIHeterocyclic Compounds, 1-RingLigandsRadiopharmaceuticalsDry mouthProstate cancerPSMATargeted radioligand therapy

Identifiers

PMID40897948
PMCPMC12628472

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.